Clinical trial
Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke
NCT00200356 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke
- Lead sponsor
- Shionogi
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- October 31, 2006
- Enrollment
- 401 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.